Board of Directors
Scientific Advisory Board
News & Events
View more: CM-24 references
more about CM-24
Jan 01, 2021
Download PDF file
News and Events
more about CM-24
more about NT-219
Purple Biotech will present in an Oral Presentation session: ‘Interim results of a Phase 1/2 trial of NT219 in combination with cetuximab in patients with advanced/metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)’ at the ESMO Targeted Anticancer Therapies Congress 2024 (ESMO TAT) February 26-28, Paris, France. Presentation date and time: February 26 at 3:45 pm, 2024
Phase 1 Study of CM24 in Combination with Nivolumab in Patients with Advanced Pancreatic Cancer – Survival, Exploratory Biomarkers and Effect on Neutrophil Extracellular Traps (NETs)
Purple Biotech will present a poster titled: ‘Phase 1 Study of CM24 in Combination with Nivolumab in Patients with Advanced Pancreatic Cancer – Survival, Potential Biomarker and Effect on Neutrophil Extracellular Traps (NETs)’ at the AACR Special Conference: Pancreatic Cancer, September 27-30, 2023. Presentation date and time: September 28 at 4:40 pm, 2023
Drug Discovery World article on NT219 poster publication on AACR23: “New drug could help overcome tumour resistance to treatment”
NT219 induces tumor PD-L1 expression and potentiates anti-PD-1efficacy
Purple Biotech to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023.
Purple Biotech Presents NT219 Pre-Clinical Data at the AACR 2023 Annual Meeting.
Purple Biotech’s CEO Gil Efron is featured in Pharma’s Almanac sharing his insights in a Q&A executive interview. Read the full Q&A here.
Purple Biotech to attend the 17th annual BIO-Europe Spring taking place March 20-22, Basel, Switzerland.
Purple Biotech CEO Gil Efron is featured in Drug Development and Delivery Magazine in a Q&A executive interview. Read the full interview.
Skip to content